Metoclopramide Darnytsia solution for injection 5 mg/ml in 2 ml ampoules 10 pcs.

Active ingredient: metoclopramide;

1 ml of solution contains metoclopramide hydrochloride 5 mg;

Excipients: sodium chloride, disodium edetate, sodium sulfite anhydrous (E 221), propylene glycol, diluted hydrochloric acid, water for injections.

• hypersensitivity to metoclopramide or to any other component of the drug;
• gastrointestinal bleeding;
• mechanical intestinal obstruction;
• gastrointestinal perforation;
• confirmed or suspected pheochromocytoma (due to the risk of severe attacks of arterial hypertension);
• history of tardive dyskinesia caused by neuroleptics or metoclopramide;
• epilepsy (increased frequency and intensity of seizures);
• Parkinson’s disease;
• simultaneous use with levodopa or dopaminergic agonists;
• established methemoglobinemia with metoclopramide or a history of NADH-cytochrome-b5-reductase deficiency;
• prolactin-dependent tumors;
• increased seizure readiness (extrapyramidal movement disorders);
• patient’s age up to 1 year (due to the risk of developing extrapyramidal disorders).

Due to the content of sodium sulfite, the drug should not be prescribed to patients with bronchial asthma with hypersensitivity to sulfites.

The solution for injection should be administered intramuscularly or intravenously as a slow bolus injection over at least 3 minutes.

Use 0.9% sodium chloride solution, 5% glucose solution as a solvent.

Pregnant women

Metoclopramide can be used during pregnancy if clinically necessary. Due to its pharmacological properties (as with other neuroleptics), the possibility of extrapyramidal syndrome in the newborn cannot be excluded if metoclopramide is used late in pregnancy. Metoclopramide should be avoided late in pregnancy. The newborn should be observed when metoclopramide is used.

Children

Metoclopramide is contraindicated in children under 1 year of age.

Drivers

When using the drug, you should refrain from potentially dangerous activities that require increased attention (driving, working with other mechanisms).

Symptoms: drowsiness, decreased level of consciousness, confusion, irritability, anxiety and its increase, convulsions, extrapyramidal-motor disorders, impaired function of the cardiovascular system with bradycardia and increased or decreased blood pressure, hallucinations, respiratory and cardiac arrest, dystonic reactions. Isolated cases of methemoglobinemia have been reported.

Treatment: Extrapyramidal disorders are eliminated by slow administration of the antidote biperiden. In the case of the use of large doses of metoclopramide, it must be removed from the gastrointestinal tract by gastric lavage or by taking activated charcoal and sodium sulfate. Vital functions of the body are monitored until the symptoms of poisoning disappear completely.

In adolescents and patients with severe renal impairment (renal failure), as a result of which the excretion of metoclopramide is slowed down, the development of side effects should be monitored especially closely. If they occur, the use of the drug should be discontinued immediately.

The risk of developing adverse reactions from the nervous system increases when using the drug in high doses and with prolonged use.

Contraindicated combinations: Levodopa or dopaminergic agonists and metoclopramide are characterized by mutual antagonism.

Combinations to avoid: Alcohol enhances the sedative effect of metoclopramide.

Store out of the reach of children in the original packaging at a temperature not exceeding 25 °C.

Do not freeze.

Shelf life – 4 years.